Instil Bio TIL 深 沪
已收盘 08-22 16:00:00 美东时间
26.99
+0.480
+1.81%
华盛通- 最 高27.8362
- 今 开26.85
- 成交量 6.52万股
- 最 低 26.36
- 昨 收 26.51
- 总市值 1.76亿
- 52周最高 92.00
- 市盈率 静 --
- 换手率 1.00%
- 52周最低 10.80
- 委 比 -39.23%
- 总股本 650.40万
- 历史最高 589.80
- 量 比 0.57
- 振 幅 5.57%
- 历史最低 0.80
- 每 手 1
- 风险率 12.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多V.S.T Tillers Tractors Announces 57th AGM and Proposed Dividend
VST Tillers Tractors Limited ( ($IN:VSTTILLERS) ) has shared an update. V.S.T T...
08-20 03:25
Prairie Operating plummets as Piper Sandler downgrades on dilution warning
Prairie Operating (NASDAQ:PROP) -19.6% in Tuesday's trading as Piper Sandler downgraded the oil and gas exploration company to Neutral from Overweight with a $3 price target, slashed from $9, followin...
08-20 02:28
Iovance Biotherapeutics Receives Health Canada NOC/c For Amtagvi
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapySAN CARLOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Iovance
08-19 04:24
【爱建医药】创新药板块即将迎来新一轮催化，关注WCLC、ESMO等研究成果揭晓
（来源：爱建证券研究所） WEEKLY REPORT 创新药板块即将迎来新一轮催化， 关注WCLC、ESMO等研究成果揭晓 -爱建生物医药行业周报- 本报告发布...
08-18 16:51
HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $125 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $125 price target.
08-15 19:24
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure...
08-15 00:22
国金医药甘坛焕丨创新药前瞻深度：从IL-2双抗，看TAA、细胞及趋化因子的PD-1升级新方向
（来源：国金证券研究所） 作者：甘坛焕、赵海春 摘要 背景 创新药BD（授权合作交易）及其首付额爆发，下一个十亿美元首付花落谁家成市场新焦点。（...
08-14 07:34
Instil Bio Non-GAAP EPS of -$3.24
Instil Bio press release (NASDAQ:TIL): Q2 Non-GAAP EPS of -$3.24. As of June 30, 2025, Instil had cash, cash equivalents, restricted cash, marketable securities and long-term investments of $103.6 mil...
08-13 20:37
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio reported its Q2 2025 financial results and provided updates. Key highlights include the appointment of a Chief Medical Officer, clearance of the IND application for '2510, and preliminary safety and efficacy data from a Phase 2 study in China. The company anticipates initiating the U.S. clinical trial for '2510 before the end of 2025 and presenting updated monotherapy data at IASLC's 2025 World Conference on Lung Cancer. Financially, I...
08-13 10:00
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology
Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (N...
08-12 20:05
